Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
18 evidence topics · 17 sources
US adults with NASH and non-cirrhotic F2 to F3 fibrosis: prevalence inputs of an eligible-population model
“In the base case, a NASH prevalence of 4.6% was modeled (range 1.3–14.2%). This value was multiplied by the proportion estimated to have non-cirrhotic MALF (i.e., 35%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, taking patient counts estimates using FIB-4 for F2 and F3 over the total subgroup patient count, we get (3735 + 2725)/18,612 ≈ 35% of the patients were diagnosed with F2/F3 NASH (Table 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assuming a 1-million commercial-member population, the resmetirom treatment-eligible population was estimated as 1255–1699 in Years 1–3 following approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with NASH and moderate to severe fibrosis: ICER budget impact population, 2023 to 2027
US adults meeting liberal and restrictive resmetirom eligibility criteria, NHANES 2017 to March 2020
“Two eligibility scenarios were examined: a liberal scenario requiring ALT >17 U/L for women or >20 U/L for men, controlled attenuation parameter (CAP) >280 dB/m, and liver stiffness measurement (LSM) >8 kPa; and a restrictive scenario requiring ALT >30 U/L for both sexes, CAP >280 dB/m, and LSM >10 kPa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An estimated 8.3 million (95% CI: 6.6–9.9 million) adults met the liberal eligibility criteria, while 2.3 million (95% CI: 1.4–3.2 million) met the restrictive criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among adults with T2DM, 3.5 million (95% CI: 2.4–4.5 million; 12.2%) met liberal, whereas 0.85 million (95% CI: 0.5–1.2 million; 3.0%) restrictive criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with NAFLD: at-risk NASH by FAST score (proxy for NAS of 4 or more and F2 or higher), NHANES 2017 to 2018
“Patients with a FAST score >0.35 were considered to have at-risk NASH, defined as NASH with NAFLD activity score ≥4 and fibrosis stage ≥2 on liver biopsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall prevalence of at-risk NASH was 11.6% (95% CI: 8.8–15.1) and was higher in males than females (15.8% vs. 6.5%; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated ~9 million people in the US have at-risk NASH and may benefit from active surveillance and therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with MASLD by liver stiffness: 8 to 12 kPa and 12 kPa or higher, NHANES 2017 to 2020
US adults aged 50 years or older with type 2 diabetes: MASLD, at-risk MASH, and cirrhosis, prospective cohort 2016 to 2023
“This prospective study enrolled adults age ≥ 50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis was 69.6%, 13.6%, and 6.8%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At-risk MASH was defined by an either positive MEFIB score (MRE > 3.3 kPa + Fib4 > 1.6), FAST score ≥ 0.67, or MAST score ≥ 0.242” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with SLD, MASLD, and MetALD, NHANES January 2017 to March 2020
“Among 7367 participants, 2549 met the new definition for SLD (mean age 51 years, 57.7% male, 63.2% non-Hispanic White; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated prevalence of SLD was 34.2% (95% CI 31.9%–36.5%): MASLD 31.3% (95% CI 29.2%–33.4%), MetALD 2.2% (95%CI 1.6–2.9%), ALD 0.7% (95%CI 0.5–0.9%) and etiology-specific or cryptogenic SLD 0.03% (95% CI 0.01%–0.08%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this national study, we estimate the prevalence of SLD to be 34.2% (ie, > 90 million US adults), with MASLD accounting for the majority (31.3%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with SLD and MASLD, age-adjusted, and advanced fibrosis in SLD, NHANES 2017 to 2023
“Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US general population with MASLD and MASLD-related cirrhosis, NHANES 2017 to 2020
“The prevalence of chronic liver disease etiologies was ALD 0.85%, MetALD 3.38%, CHB 0.23%, CHC 0.73%, ALD + viral hepatitis 0.16%, and MASLD 33.05%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with MASLD comprise the majority of US residents with cirrhosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
US adults with NAFLD and NASH: prevalence and clinically significant fibrosis in AASLD 2023 guidance
“The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study also highlights that since the publication of a prior prospective prevalence study,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased > 2-fold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US NAFLD and NASH cases with F3 to F4 fibrosis, 2015 and projected to 2030, Markov model
“The total NAFLD population in 2015 was estimated at 83.1 million cases (Fig. 3A), with a prevalence rate of 30.0% among the population aged ≥15 years and 25.8% among all ages. By 2030, the NAFLD population was projected to increase 21% to 100.9 million cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of NASH cases is projected to increase 63% from 16.52 million cases in 2015 to 27.00 million in 2030 (Fig. 3B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among NASH cases in 2015, an estimated 20% have F3/F4 fibrosis or advanced liver disease, encompassing approximately 3.31 million cases (Fig. 4). By 2030, this number is expected to increase over 160% to 7.94 million cases and will account for 29% of NASH cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US adults with MASLD, MASH, and MASH with F2 or higher fibrosis, projected 2020 to 2050, microsimulation model
“The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050. Cases of MASH would increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050. The number of cases of MASH and clinically significant fibrosis (ie, F≥F2, centrilobular and periportal fibrosis or more severe disease) were estimated to increase from 6.7 million to 11.7 million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global and North American NAFLD prevalence: meta-analysis of studies from 1990 to 2019
“Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across the entire study period (1990–2019), analysis of the regional prevalence rates showed a prevalence of 31.20% in North America and Australia (95% CI: 25.86%–37.08%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global and North American NASH prevalence: estimate from voluntarily biopsied NAFLD cohorts
“Subsequently, the NASH prevalence in the general population was estimated by multiplying the prevalence of NASH in the “voluntary biopsied NAFLD” group with the prevalence of NAFLD in the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our estimates suggest that the global NASH prevalence is 5.27% (SE: 2.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“North America [5.00% (2.50)]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of NASH among NAFLD patients is 16.02% (95% CI: 3.24%–52.08%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global NAFLD prevalence in adults diagnosed by imaging: meta-analysis
“The overall prevalence of NAFLD worldwide was estimated to be 32·4% (95% CI 29·9-34·9). Prevalence increased significantly over time, from 25·5% (20·1-31·0) in or before 2005 to 37·8% (32·4-43·3) in 2016 or later (p=0·013). Overall prevalence of NAFLD was significantly higher in men than in women (39·7% [36·6-42·8] vs 25·6% [22·3-28·8]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global NAFLD prevalence and metabolic comorbidities: meta-analysis of studies from 1989 to 2015
“Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global NAFLD prevalence forecast to 2040, hierarchical Bayesian model
UK Biobank participants with liver MRI: SLD, MASLD, and at-risk MASH
“At-risk MASH was defined as PDFF≥5% and cT1 ≥875 ms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 40,189 patients, 10,886 (27.0%) had a PDFF ≥5%, indicating SLD. Among patients with SLD, 1% had ALD, 89.0% had MASLD, 7.9% had MetALD and 2.2% had at-risk MASH. The at-risk MASH group, which included 0.6% of the general population, had the highest mean liver fat on MRI and the highest BMI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote